Fabio Farinati

Fabio Farinati

Fabio Farinati

Professor - Department of Surgery, Oncology and Gastroenterology

Phone: 3389346770
Email: fabio.farinati@unipd.it
Address: Section Gastroenterology, Giustinianeo Hospital
Via Nicolò Giustiani 2, Padova 35128

Research description

Clinical and translational research on GI oncology, in particular with respect to liver and gastric cancer, with special interest at the moment in liquid biopsy studies, specifically in miRNA and liver cancer and gastric precancerous condition. In the clinical field, studies on the management of liver cancer.

 

Relevant publications

Genetically determined telomere length is associated with pancreatic neuroendocrine neoplasms onset. Gentiluomo M, Capurso G, Morelli L, Ermini S, Pasquali C, Latiano A, Tavano F, Greenhalf W, Milanetto AC, Landi S, Roth S, Malecka-Wojciesko E, Costello E, Jamroziak K, Perri F, Boggi U, Basso D, Farinati F, Kaaks R, Vanella G, Gais Zurcher AJ, Archibugi L, Lawlor RT, Canzian F, Campa D.Neuroendocrinology. 2022 Apr 26. doi: 10.1159/000524659. Online ahead of print.PMID: 35472852
Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist? Angerilli V, Lonardi S, Farinati F, Savarino E, Bergamo F, Fassan M.Histopathology. 2022 Jun;80(7):1138-1140. doi: 10.1111/his.14647. Epub 2022 Apr 5.PMID: 35384038 No abstract available.
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Giannini EG, Pieri G, Labanca S, Plaz Torres MC, Gasbarrini A, Biasini E, Campani C, Cazzagon N, Foschi FG, Mega A, Masotto A, Raimondo G, Rapaccini GL, Sacco R, Caturelli E, Guarino M, Tovoli F, Vidili G, Brunetto MR, Nardone G, Svegliati-Baroni G, Magalotti D, Azzaroli F, Cabibbo G, Di Marco M, Sangiovanni A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Study Group.Dig Liver Dis. 2022 Mar 27:S1590-8658(22)00205-5. doi: 10.1016/j.dld.2022.03.002. Online ahead of print.PMID: 35354543
 Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F.Front Oncol. 2022 Jan 31;12:822507. doi: 10.3389/fonc.2022.822507. eCollection 2022.PMID: 35174092 Free PMC article.
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Zanetto A, Campello E, Pelizzaro F, Farinati F, Burra P, Simioni P, Senzolo M.Liver Int. 2022 Feb 7. doi: 10.1111/liv.15183. Online ahead of print.PMID: 35129286 Review.
Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F.Int J Mol Sci. 2022 Jan 2;23(1):500. doi: 10.3390/ijms23010500.PMID: 35008926 Free PMC article. Review.
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group.Gut. 2021 Dec 21:gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915. Online ahead of print.PMID: 34933916
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP.Cancers (Basel). 2021 Sep 29;13(19):4882. doi: 10.3390/cancers13194882.PMID: 34638365 Free PMC article. 
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group.Dig Liver Dis. 2021 Sep 24:S1590-8658(21)00766-0. doi: 10.1016/j.dld.2021.08.025. Online ahead of print.PMID: 34580038
Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. Businello G, Angerilli V, Parente P, Realdon S, Savarino E, Farinati F, Grillo F, Vanoli A, Galuppini F, Paccagnella S, Pennelli G, Mastracci L, Saragoni L, Fassan M.Int J Mol Sci. 2021 Sep 14;22(18):9950. doi: 10.3390/ijms22189950.PMID: 34576114 Free PMC article. Review

Fundings

Gilead, Bayer, Roche, Italian Ministry of University